Randomised controlled trial of multiple drugs combined therapy for diffuse IgA nephropathy

Randomised controlled trial of multiple drugs combined therapy for diffuse IgA nephropathy - Randomised controlled trial of multiple drugs combined therapy for diffuse IgA nephropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000341

Enrollment

Registered

2006-03-31

Start date

2004-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory IgA nephropathy

Interventions

Prednisolone and anti-thrombocyte and angiotensin II receptor blocker or angiotensin converting enzyme inhibitor inhibitor mizoribine and Prednisolone and anti thrombocyte and angiotensin II receptor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: IgA nephropathy patients who underwent renal biopsy. Patients who diagnosed to have diffuse IgA nephropathy Age 16-75 years Urine protein excretion of over 0.5g daily

Exclusion criteria

Exclusion criteria: patients who's Ccr. Are Under 50ml/min or s-Cr. are over 2.0 mg/dl patients who have severe liver dysfunction pregnant or nursing women patients with a hypersensitivity to each thrapy drugs Judged inapproopriate for the physicians

Design outcomes

Primary

Measure	Time frame
Changing percentage of Ccr and urinary protein.	—

Countries

Japan

Contacts

Public ContactTetsuya Mitarai

Japanese Study Group of Multiple drug therapy for IgAN Department of Nephrology and Hypertension, Saitama Medical Center, Saitama Medical School

mitarai@saitama-med.ac.jp049-228-3604

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026